Kodiak Sciences Inc. (NYSE:KOD) SVP Sells $157,800.00 in Stock
Kodiak Sciences Inc. (NYSE:KOD) SVP Hong Liang sold 4,000 shares of the company’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $39.45, for a total value of $157,800.00. Following the completion of the sale, the senior vice president now directly owns 140,212 shares in the company, valued at approximately $5,531,363.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of NYSE:KOD opened at $46.42 on Thursday. Kodiak Sciences Inc. has a 52-week low of $5.86 and a 52-week high of $82.75. The stock’s fifty day simple moving average is $58.45 and its 200-day simple moving average is $44.59.
Kodiak Sciences (NYSE:KOD) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.05).
Several analysts have weighed in on KOD shares. Zacks Investment Research raised Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Thursday, February 20th. Goldman Sachs Group started coverage on Kodiak Sciences in a report on Monday, March 2nd. They issued a “buy” rating and a $80.00 target price on the stock. SunTrust Banks started coverage on Kodiak Sciences in a report on Wednesday, February 5th. They issued a “buy” rating and a $101.00 target price on the stock. JPMorgan Chase & Co. started coverage on Kodiak Sciences in a report on Tuesday, December 24th. They issued an “overweight” rating and a $82.00 target price on the stock. Finally, Barclays lowered Kodiak Sciences from an “overweight” rating to an “equal weight” rating and set a $69.00 target price on the stock. in a report on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $84.30.
About Kodiak Sciences
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.
Recommended Story: Understanding each part of a balance sheet
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.